25 XP   0   0   10

Aslan Pharmaceuticals Ltd ADR
Buy, Hold or Sell?

Let's analyse Aslan Pharmaceuticals Ltd ADR together

PenkeI guess you are interested in Aslan Pharmaceuticals Ltd ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aslan Pharmaceuticals Ltd ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aslan Pharmaceuticals Ltd ADR

I send you an email if I find something interesting about Aslan Pharmaceuticals Ltd ADR.

Quick analysis of Aslan Pharmaceuticals Ltd ADR (30 sec.)










What can you expect buying and holding a share of Aslan Pharmaceuticals Ltd ADR? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.01
Expected worth in 1 year
$-0.33
How sure are you?
22.2%

+ What do you gain per year?

Total Gains per Share
$-0.34
Return On Investment
-76.2%

For what price can you sell your share?

Current Price per Share
$0.45
Expected price per share
$0.392 - $1.045
How sure are you?
50%

1. Valuation of Aslan Pharmaceuticals Ltd ADR (5 min.)




Live pricePrice per Share (EOD)

$0.45

Intrinsic Value Per Share

$-23.55 - $-15.68

Total Value Per Share

$-23.54 - $-15.67

2. Growth of Aslan Pharmaceuticals Ltd ADR (5 min.)




Is Aslan Pharmaceuticals Ltd ADR growing?

Current yearPrevious yearGrowGrow %
How rich?$256.8k$1.7m-$1.5m-585.0%

How much money is Aslan Pharmaceuticals Ltd ADR making?

Current yearPrevious yearGrowGrow %
Making money-$51.3m-$34.7m-$16.6m-32.4%
Net Profit Margin-428.2%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Aslan Pharmaceuticals Ltd ADR (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#857 / 1010

Most Revenue
#285 / 1010

Most Profit
#893 / 1010

Most Efficient
#719 / 1010

What can you expect buying and holding a share of Aslan Pharmaceuticals Ltd ADR? (5 min.)

Welcome investor! Aslan Pharmaceuticals Ltd ADR's management wants to use your money to grow the business. In return you get a share of Aslan Pharmaceuticals Ltd ADR.

What can you expect buying and holding a share of Aslan Pharmaceuticals Ltd ADR?

First you should know what it really means to hold a share of Aslan Pharmaceuticals Ltd ADR. And how you can make/lose money.

Speculation

The Price per Share of Aslan Pharmaceuticals Ltd ADR is $0.448. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aslan Pharmaceuticals Ltd ADR.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aslan Pharmaceuticals Ltd ADR, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.01. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aslan Pharmaceuticals Ltd ADR.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.92-651.8%-2.92-651.8%-1.78-397.3%-18.09-4,037.8%-22.46-5,014.3%
Usd Book Value Change Per Share-0.09-19.1%-0.09-19.1%0.1226.3%-0.01-2.1%0.000.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.09-19.1%-0.09-19.1%0.1226.3%-0.01-2.1%0.000.4%
Usd Price Per Share0.36-0.36-1.12-1.79-0.99-
Price to Earnings Ratio-0.12--0.12--0.63--0.85--0.47-
Price-to-Total Gains Ratio-4.22--4.22-9.52--113.22--113.22-
Price to Book Ratio24.67-24.67-11.20--385.77--214.32-
Price-to-Total Gains Ratio-4.22--4.22-9.52--113.22--113.22-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.448
Number of shares2232
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.09-0.01
Usd Total Gains Per Share-0.09-0.01
Gains per Quarter (2232 shares)-190.56-21.12
Gains per Year (2232 shares)-762.26-84.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-762-7720-84-94
20-1525-15340-169-178
30-2287-22960-253-262
40-3049-30580-338-346
50-3811-38200-422-430
60-4574-45820-507-514
70-5336-53440-591-598
80-6098-61060-676-682
90-6860-68680-760-766
100-7623-76300-845-850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.09.00.00.0%0.09.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%2.07.00.022.2%2.07.00.022.2%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.09.00.0%0.00.09.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%2.07.00.022.2%2.07.00.022.2%

Fundamentals of Aslan Pharmaceuticals Ltd ADR

About Aslan Pharmaceuticals Ltd ADR

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Fundamental data was last updated by Penke on 2024-04-11 01:09:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Aslan Pharmaceuticals Ltd ADR.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Aslan Pharmaceuticals Ltd ADR earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aslan Pharmaceuticals Ltd ADR to the Biotechnology industry mean.
  • A Net Profit Margin of -428.2% means that $-4.28 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is -428.2%. The company is making a huge loss. -2
  • The TTM is -428.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-428.2%TTM-428.2%0.0%
TTM-428.2%YOY--428.2%
TTM-428.2%5Y-399.4%-28.8%
5Y-399.4%10Y-230.6%-168.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-428.2%-207.2%-221.0%
TTM-428.2%-216.8%-211.4%
YOY--282.3%+282.3%
5Y-399.4%-436.8%+37.4%
10Y-230.6%-597.3%+366.7%
1.1.2. Return on Assets

Shows how efficient Aslan Pharmaceuticals Ltd ADR is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aslan Pharmaceuticals Ltd ADR to the Biotechnology industry mean.
  • -2,735.4% Return on Assets means that Aslan Pharmaceuticals Ltd ADR generated $-27.35 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is -2,735.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2,735.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2,735.4%TTM-2,735.4%0.0%
TTM-2,735.4%YOY-1,196.2%-1,539.3%
TTM-2,735.4%5Y-3,344.6%+609.1%
5Y-3,344.6%10Y-2,846.6%-498.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,735.4%-13.3%-2,722.1%
TTM-2,735.4%-12.8%-2,722.6%
YOY-1,196.2%-11.6%-1,184.6%
5Y-3,344.6%-13.8%-3,330.8%
10Y-2,846.6%-15.6%-2,831.0%
1.1.3. Return on Equity

Shows how efficient Aslan Pharmaceuticals Ltd ADR is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aslan Pharmaceuticals Ltd ADR to the Biotechnology industry mean.
  • -20,007.8% Return on Equity means Aslan Pharmaceuticals Ltd ADR generated $-200.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is -20,007.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20,007.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20,007.8%TTM-20,007.8%0.0%
TTM-20,007.8%YOY-1,973.0%-18,034.8%
TTM-20,007.8%5Y-5,293.7%-14,714.0%
5Y-5,293.7%10Y-3,434.9%-1,858.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20,007.8%-16.9%-19,990.9%
TTM-20,007.8%-16.1%-19,991.7%
YOY-1,973.0%-14.9%-1,958.1%
5Y-5,293.7%-19.3%-5,274.4%
10Y-3,434.9%-20.1%-3,414.8%

1.2. Operating Efficiency of Aslan Pharmaceuticals Ltd ADR.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Aslan Pharmaceuticals Ltd ADR is operating .

  • Measures how much profit Aslan Pharmaceuticals Ltd ADR makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aslan Pharmaceuticals Ltd ADR to the Biotechnology industry mean.
  • An Operating Margin of -399.0% means the company generated $-3.99  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is -399.0%. The company is operating very inefficient. -2
  • The TTM is -399.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-399.0%TTM-399.0%0.0%
TTM-399.0%YOY--399.0%
TTM-399.0%5Y-383.7%-15.4%
5Y-383.7%10Y-221.3%-162.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-399.0%-298.0%-101.0%
TTM-399.0%-238.5%-160.5%
YOY--288.4%+288.4%
5Y-383.7%-486.2%+102.5%
10Y-221.3%-628.4%+407.1%
1.2.2. Operating Ratio

Measures how efficient Aslan Pharmaceuticals Ltd ADR is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.02 means that the operating costs are $4.02 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is 4.018. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.018. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.018TTM4.0180.000
TTM4.018YOY-+4.018
TTM4.0185Y4.042-0.024
5Y4.04210Y2.440+1.602
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0183.235+0.783
TTM4.0183.310+0.708
YOY-3.838-3.838
5Y4.0425.679-1.637
10Y2.4407.823-5.383

1.3. Liquidity of Aslan Pharmaceuticals Ltd ADR.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Aslan Pharmaceuticals Ltd ADR is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.63 means the company has $2.63 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is 2.628. The company is able to pay all its short-term debts. +1
  • The TTM is 2.628. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.628TTM2.6280.000
TTM2.628YOY14.752-12.124
TTM2.6285Y5.322-2.694
5Y5.32210Y7.336-2.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6283.863-1.235
TTM2.6284.169-1.541
YOY14.7525.337+9.415
5Y5.3226.122-0.800
10Y7.3366.434+0.902
1.3.2. Quick Ratio

Measures if Aslan Pharmaceuticals Ltd ADR is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aslan Pharmaceuticals Ltd ADR to the Biotechnology industry mean.
  • A Quick Ratio of 2.46 means the company can pay off $2.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is 2.456. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.456. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.456TTM2.4560.000
TTM2.456YOY14.184-11.727
TTM2.4565Y5.157-2.701
5Y5.15710Y7.233-2.076
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4563.504-1.048
TTM2.4563.991-1.535
YOY14.1845.371+8.813
5Y5.1576.088-0.931
10Y7.2336.395+0.838

1.4. Solvency of Aslan Pharmaceuticals Ltd ADR.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Aslan Pharmaceuticals Ltd ADR assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aslan Pharmaceuticals Ltd ADR to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.86 means that Aslan Pharmaceuticals Ltd ADR assets are financed with 86.3% credit (debt) and the remaining percentage (100% - 86.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is 0.863. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.863. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.863TTM0.8630.000
TTM0.863YOY0.394+0.470
TTM0.8635Y0.867-0.004
5Y0.86710Y1.401-0.534
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8630.339+0.524
TTM0.8630.337+0.526
YOY0.3940.271+0.123
5Y0.8670.368+0.499
10Y1.4010.388+1.013
1.4.2. Debt to Equity Ratio

Measures if Aslan Pharmaceuticals Ltd ADR is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aslan Pharmaceuticals Ltd ADR to the Biotechnology industry mean.
  • A Debt to Equity ratio of 631.4% means that company has $6.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aslan Pharmaceuticals Ltd ADR:

  • The MRQ is 6.314. The company is unable to pay all its debts with equity. -1
  • The TTM is 6.314. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ6.314TTM6.3140.000
TTM6.314YOY0.649+5.665
TTM6.3145Y1.538+4.776
5Y1.53810Y0.936+0.602
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3140.392+5.922
TTM6.3140.403+5.911
YOY0.6490.335+0.314
5Y1.5380.427+1.111
10Y0.9360.461+0.475

2. Market Valuation of Aslan Pharmaceuticals Ltd ADR

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aslan Pharmaceuticals Ltd ADR generates.

  • Above 15 is considered overpriced but always compare Aslan Pharmaceuticals Ltd ADR to the Biotechnology industry mean.
  • A PE ratio of -0.12 means the investor is paying $-0.12 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aslan Pharmaceuticals Ltd ADR:

  • The EOD is -0.153. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.123. Based on the earnings, the company is expensive. -2
  • The TTM is -0.123. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.153MRQ-0.123-0.030
MRQ-0.123TTM-0.1230.000
TTM-0.123YOY-0.629+0.506
TTM-0.1235Y-0.853+0.730
5Y-0.85310Y-0.474-0.379
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.153-2.300+2.147
MRQ-0.123-2.656+2.533
TTM-0.123-2.718+2.595
YOY-0.629-4.145+3.516
5Y-0.853-6.258+5.405
10Y-0.474-6.315+5.841
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aslan Pharmaceuticals Ltd ADR:

  • The EOD is -0.205. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.165. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.165. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.205MRQ-0.165-0.040
MRQ-0.165TTM-0.1650.000
TTM-0.165YOY-0.579+0.414
TTM-0.1655Y-1.056+0.891
5Y-1.05610Y-0.587-0.469
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.205-2.974+2.769
MRQ-0.165-3.306+3.141
TTM-0.165-3.508+3.343
YOY-0.579-5.613+5.034
5Y-1.056-8.378+7.322
10Y-0.587-8.873+8.286
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Aslan Pharmaceuticals Ltd ADR is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 24.67 means the investor is paying $24.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aslan Pharmaceuticals Ltd ADR:

  • The EOD is 30.698. Based on the equity, the company is expensive. -2
  • The MRQ is 24.668. Based on the equity, the company is expensive. -2
  • The TTM is 24.668. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD30.698MRQ24.668+6.030
MRQ24.668TTM24.6680.000
TTM24.668YOY11.203+13.465
TTM24.6685Y-385.768+410.436
5Y-385.76810Y-214.316-171.453
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD30.6981.914+28.784
MRQ24.6682.116+22.552
TTM24.6682.097+22.571
YOY11.2032.881+8.322
5Y-385.7683.550-389.318
10Y-214.3163.936-218.252
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aslan Pharmaceuticals Ltd ADR.

3.1. Institutions holding Aslan Pharmaceuticals Ltd ADR

Institutions are holding 14.896% of the shares of Aslan Pharmaceuticals Ltd ADR.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30TANG CAPITAL MANAGEMENT LLC10.80610.5044190155277348468.5671
2023-09-30Bvf Inc5.96690.0524104999900
2023-12-31UBS Group AG3.55170.00016250006250000
2023-12-31Shay Capital LLC2.27310.04184000004000000
2023-12-31Sio Capital Management, LLC1.44430.030225415000
2023-12-31Renaissance Technologies Corp0.9820.0001172801139341416.4405
2023-09-30Citadel Advisors Llc0.98020.0001172478150.0087
2023-12-31Parkman Healthcare Partners LLC0.62880.0081110658-262083-70.3124
2023-09-30Schonfeld Strategic Advisors LLC0.520.0013915003710068.1985
2023-12-31LANDSCAPE CAPITAL MANAGEMENT,LLC0.47310.003983259832590
2023-12-31Millennium Management LLC0.4567080362-94-0.1168
2023-12-31Waterfront Wealth Inc.0.23270.006340941-8500-17.1922
2023-12-31Ikarian Capital, LLC0.20130.00063542000
2023-12-31XTX Topco Ltd0.15720.003227666276660
2023-12-31Morgan Stanley - Brokerage Accounts0.1404024700-4258-14.7041
2023-12-31JANE STREET GROUP, LLC0.1312023093230930
2023-12-31Onyx Bridge Wealth Group LLC0.12920.002422727227270
2023-12-31Temasek Holdings Ltd.0.08910.000115682-319933-95.3274
2023-12-31Capital Analysts Inc.0.01160.0001203900
2023-12-31Rhumbline Advisers0.00740129400
Total 29.1830.65515135321+1536817+29.9%

3.2. Funds holding Aslan Pharmaceuticals Ltd ADR

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Nasdaq Composite Index0.03520.0001796800
2024-03-28SPDR® Portfolio Emerging Markets ETF0.0008018500
2023-09-30NT Tax Advantaged BONY EM0.00040.00148800
Total 0.03640.0015824100.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aslan Pharmaceuticals Ltd ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.085-0.0850%0.118-173%-0.009-89%0.002-5365%
Book Value Per Share--0.0150.0150%0.100-85%0.030-51%0.019-25%
Current Ratio--2.6282.6280%14.752-82%5.322-51%7.336-64%
Debt To Asset Ratio--0.8630.8630%0.394+119%0.8670%1.401-38%
Debt To Equity Ratio--6.3146.3140%0.649+872%1.538+311%0.936+574%
Dividend Per Share----0%-0%-0%-0%
Eps---2.920-2.9200%-1.780-39%-18.089+520%-22.464+669%
Free Cash Flow Per Share---2.184-2.1840%-1.935-11%-1.999-8%-1.482-32%
Free Cash Flow To Equity Per Share---1.916-1.9160%4.309-144%0.067-2975%0.360-633%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---15.682--------
Intrinsic Value_10Y_min---23.554--------
Intrinsic Value_1Y_max---1.643--------
Intrinsic Value_1Y_min---2.112--------
Intrinsic Value_3Y_max---4.882--------
Intrinsic Value_3Y_min---6.598--------
Intrinsic Value_5Y_max---8.056--------
Intrinsic Value_5Y_min---11.326--------
Market Cap7883500.800+20%6334956.0006334956.0000%19708752.000-68%31463614.800-80%17479786.000-64%
Net Profit Margin---4.282-4.2820%--100%-3.994-7%-2.306-46%
Operating Margin---3.990-3.9900%--100%-3.837-4%-2.213-45%
Operating Ratio--4.0184.0180%-+100%4.042-1%2.440+65%
Pb Ratio30.698+20%24.66824.6680%11.203+120%-385.768+1664%-214.316+969%
Pe Ratio-0.153-24%-0.123-0.1230%-0.629+410%-0.853+592%-0.474+285%
Price Per Share0.448+20%0.3600.3600%1.120-68%1.788-80%0.993-64%
Price To Free Cash Flow Ratio-0.205-24%-0.165-0.1650%-0.579+251%-1.056+541%-0.587+256%
Price To Total Gains Ratio-5.247-24%-4.217-4.2170%9.517-144%-113.220+2585%-113.220+2585%
Quick Ratio--2.4562.4560%14.184-83%5.157-52%7.233-66%
Return On Assets---27.354-27.3540%-11.962-56%-33.446+22%-28.466+4%
Return On Equity---200.078-200.0780%-19.730-90%-52.937-74%-34.349-83%
Total Gains Per Share---0.085-0.0850%0.118-173%-0.009-89%0.002-5365%
Usd Book Value--256812.254256812.2540%1759224.910-85%525163.029-51%342863.251-25%
Usd Book Value Change Per Share---0.085-0.0850%0.118-173%-0.009-89%0.002-5365%
Usd Book Value Per Share--0.0150.0150%0.100-85%0.030-51%0.019-25%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---2.920-2.9200%-1.780-39%-18.089+520%-22.464+669%
Usd Free Cash Flow---38432358.000-38432358.0000%-34044358.000-11%-35178626.200-8%-26081681.889-32%
Usd Free Cash Flow Per Share---2.184-2.1840%-1.935-11%-1.999-8%-1.482-32%
Usd Free Cash Flow To Equity Per Share---1.916-1.9160%4.309-144%0.067-2975%0.360-633%
Usd Market Cap7883500.800+20%6334956.0006334956.0000%19708752.000-68%31463614.800-80%17479786.000-64%
Usd Price Per Share0.448+20%0.3600.3600%1.120-68%1.788-80%0.993-64%
Usd Profit---51382417.000-51382417.0000%-34709218.000-32%-38649795.800-25%-29294806.270-43%
Usd Revenue--12000000.00012000000.0000%-+100%3000000.000+300%2943217.252+308%
Usd Total Gains Per Share---0.085-0.0850%0.118-173%-0.009-89%0.002-5365%
 EOD+5 -3MRQTTM+0 -0YOY+2 -315Y+8 -2510Y+7 -26

4.2. Fundamental Score

Let's check the fundamental score of Aslan Pharmaceuticals Ltd ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.153
Price to Book Ratio (EOD)Between0-130.698
Net Profit Margin (MRQ)Greater than0-4.282
Operating Margin (MRQ)Greater than0-3.990
Quick Ratio (MRQ)Greater than12.456
Current Ratio (MRQ)Greater than12.628
Debt to Asset Ratio (MRQ)Less than10.863
Debt to Equity Ratio (MRQ)Less than16.314
Return on Equity (MRQ)Greater than0.15-200.078
Return on Assets (MRQ)Greater than0.05-27.354
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Aslan Pharmaceuticals Ltd ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.027
Ma 20Greater thanMa 500.522
Ma 50Greater thanMa 1000.602
Ma 100Greater thanMa 2000.579
OpenGreater thanClose0.489
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets61,186
Total Liabilities52,820
Total Stockholder Equity8,365
 As reported
Total Liabilities 52,820
Total Stockholder Equity+ 8,365
Total Assets = 61,186

Assets

Total Assets61,186
Total Current Assets60,878
Long-term Assets307
Total Current Assets
Cash And Cash Equivalents 56,902
Other Current Assets 3,976
Total Current Assets  (as reported)60,878
Total Current Assets  (calculated)60,878
+/-0
Long-term Assets
Property Plant Equipment 293
Goodwill -5,830
Long Term Investments 9
Intangible Assets 5,836
Long-term Assets  (as reported)307
Long-term Assets  (calculated)307
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities23,164
Long-term Liabilities29,656
Total Stockholder Equity8,365
Total Current Liabilities
Short-term Debt 7,965
Short Long Term Debt 7,749
Accounts payable 12,784
Other Current Liabilities 2,415
Total Current Liabilities  (as reported)23,164
Total Current Liabilities  (calculated)30,913
+/- 7,749
Long-term Liabilities
Long term Debt 29,656
Capital Lease Obligations 216
Long-term Liabilities  (as reported)29,656
Long-term Liabilities  (calculated)29,872
+/- 216
Total Stockholder Equity
Common Stock63,020
Retained Earnings -278,387
Accumulated Other Comprehensive Income -179
Other Stockholders Equity 223,911
Total Stockholder Equity (as reported)8,365
Total Stockholder Equity (calculated)8,365
+/-0
Other
Capital Stock63,020
Cash and Short Term Investments 56,902
Common Stock Shares Outstanding 13,949
Liabilities and Stockholders Equity 61,186
Net Debt -19,281
Net Invested Capital 45,770
Net Tangible Assets 8,359
Net Working Capital 37,714
Property Plant and Equipment Gross 293
Short Long Term Debt Total 37,621



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
> Total Assets 
5,815
26,500
53,526
51,288
52,881
23,349
16,082
94,518
61,186
61,18694,51816,08223,34952,88151,28853,52626,5005,815
   > Total Current Assets 
5,644
26,346
52,935
50,600
29,093
22,272
15,502
93,781
60,878
60,87893,78115,50222,27229,09350,60052,93526,3465,644
       Cash And Cash Equivalents 
5,577
26,309
51,556
50,528
28,909
22,203
14,324
90,168
56,902
56,90290,16814,32422,20328,90950,52851,55626,3095,577
       Short-term Investments 
0
0
0
0
0
0
138
0
0
00138000000
       Net Receivables 
0
0
1,290
0
0
0
529
0
0
005290001,29000
       Other Current Assets 
67
36
89
72
184
69
649
3,613
3,976
3,9763,6136496918472893667
   > Long-term Assets 
171
154
591
688
23,788
1,078
579
737
307
3077375791,07823,788688591154171
       Property Plant Equipment 
100
86
383
443
288
766
476
233
293
29323347676628844338386100
       Long Term Investments 
0
0
0
0
247
200
0
495
9
949502002470000
       Intangible Assets 
21
430
2,727
2,493
23,081
3
0
0
5,836
5,83600323,0812,4932,72743021
       Long-term Assets Other 
50
55
124
161
172
108
103
10
8,587
8,587101031081721611245550
> Total Liabilities 
31,175
63,068
12,097
15,806
22,263
23,953
26,234
37,214
52,820
52,82037,21426,23423,95322,26315,80612,09763,06831,175
   > Total Current Liabilities 
1,626
1,951
3,790
5,973
7,998
5,383
10,657
6,357
23,164
23,1646,35710,6575,3837,9985,9733,7901,9511,626
       Short-term Debt 
29,616
0
0
0
0
265
3,791
199
7,965
7,9651993,791265000029,616
       Short Long Term Debt 
29,616
0
0
0
0
0
3,519
0
7,749
7,74903,5190000029,616
       Accounts payable 
790
143
2,269
3,895
5,316
1,872
2,320
3,117
12,784
12,7843,1172,3201,8725,3163,8952,269143790
       Other Current Liabilities 
836
1,808
1,521
2,079
2,683
3,247
267
223
2,415
2,4152232673,2472,6832,0791,5211,808836
   > Long-term Liabilities 
29,549
61,117
8,307
9,833
14,264
18,570
15,577
30,857
29,656
29,65630,85715,57718,57014,2649,8338,30761,11729,549
       Long term Debt Total 
0
2,066,865
269,692
287,051
427,138
542,819
0
0
0
000542,819427,138287,051269,6922,066,8650
       Long term Debt 
29,616
2,066,865
8,307
9,671
13,975
17,631
15,183
30,857
29,656
29,65630,85715,18317,63113,9759,6718,3072,066,86529,616
       Capital Lease Obligations 
0
0
0
0
0
755
553
199
216
21619955375500000
       Other Liabilities 
0
0
0
4,804
8,852
13,396
112
0
0
0011213,3968,8524,804000
       Long-term Liabilities Other 
0
0
0
162
290
447
112
0
0
00112447290162000
> Total Stockholder Equity
-25,360
-36,569
41,430
35,482
30,618
-1,677
-10,453
57,304
8,365
8,36557,304-10,453-1,67730,61835,48241,430-36,569-25,360
   Common Stock
6
6
35,627
43,840
51,627
61,367
61,826
63,020
63,020
63,02063,02061,82661,36751,62743,84035,62766
   Retained Earnings -278,387-227,004-195,683-179,485-132,469-93,461-48,224-37,654-25,950
   Accumulated Other Comprehensive Income -179-179-179-55-513000-1,530
   Capital Surplus 
0
114,878
1,784,994
2,660,223
3,469,709
3,623,481
0
0
0
0003,623,4813,469,7092,660,2231,784,994114,8780
   Treasury Stock000000000
   Other Stockholders Equity 
2,110
1,076
54,027
85,102
111,972
116,496
123,582
221,467
223,911
223,911221,467123,582116,496111,97285,10254,0271,0762,110



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue12,000
Cost of Revenue--
Gross Profit-12,000
 
Operating Income (+$)
Gross Profit-
Operating Expense-56,005
Operating Income-44,005-56,005
 
Operating Expense (+$)
Research Development43,580
Selling General Administrative12,703
Selling And Marketing Expenses-
Operating Expense56,00556,283
 
Net Interest Income (+$)
Interest Income713
Interest Expense-4,112
Other Finance Cost-0
Net Interest Income-3,399
 
Pretax Income (+$)
Operating Income-44,005
Net Interest Income-3,399
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-45,016-46,393
EBIT - interestExpense = -4,112
-45,188
-41,076
Interest Expense4,112
Earnings Before Interest and Taxes (EBIT)--40,904
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-45,016
Tax Provision-172
Net Income From Continuing Ops-45,188-45,188
Net Income-45,188
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net2,3883,399
 

Technical Analysis of Aslan Pharmaceuticals Ltd ADR
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aslan Pharmaceuticals Ltd ADR. The general trend of Aslan Pharmaceuticals Ltd ADR is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aslan Pharmaceuticals Ltd ADR's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aslan Pharmaceuticals Ltd ADR.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.5536 < 0.97 < 1.045.

The bearish price targets are: 0.4 > 0.392.

Tweet this
Aslan Pharmaceuticals Ltd ADR Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aslan Pharmaceuticals Ltd ADR. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aslan Pharmaceuticals Ltd ADR Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aslan Pharmaceuticals Ltd ADR. The current macd is -0.04483745.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aslan Pharmaceuticals Ltd ADR price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aslan Pharmaceuticals Ltd ADR. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aslan Pharmaceuticals Ltd ADR price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aslan Pharmaceuticals Ltd ADR Daily Moving Average Convergence/Divergence (MACD) ChartAslan Pharmaceuticals Ltd ADR Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aslan Pharmaceuticals Ltd ADR. The current adx is 33.50.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aslan Pharmaceuticals Ltd ADR shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Aslan Pharmaceuticals Ltd ADR Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aslan Pharmaceuticals Ltd ADR. The current sar is 0.71299203.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aslan Pharmaceuticals Ltd ADR Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aslan Pharmaceuticals Ltd ADR. The current rsi is 41.03. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Aslan Pharmaceuticals Ltd ADR Daily Relative Strength Index (RSI) ChartAslan Pharmaceuticals Ltd ADR Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aslan Pharmaceuticals Ltd ADR. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aslan Pharmaceuticals Ltd ADR price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Aslan Pharmaceuticals Ltd ADR Daily Stochastic Oscillator ChartAslan Pharmaceuticals Ltd ADR Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aslan Pharmaceuticals Ltd ADR. The current cci is -144.22912858.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Aslan Pharmaceuticals Ltd ADR Daily Commodity Channel Index (CCI) ChartAslan Pharmaceuticals Ltd ADR Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aslan Pharmaceuticals Ltd ADR. The current cmo is -28.68112322.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aslan Pharmaceuticals Ltd ADR Daily Chande Momentum Oscillator (CMO) ChartAslan Pharmaceuticals Ltd ADR Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aslan Pharmaceuticals Ltd ADR. The current willr is -90.11532125.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Aslan Pharmaceuticals Ltd ADR Daily Williams %R ChartAslan Pharmaceuticals Ltd ADR Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aslan Pharmaceuticals Ltd ADR.

Aslan Pharmaceuticals Ltd ADR Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aslan Pharmaceuticals Ltd ADR. The current atr is 0.09009233.

Aslan Pharmaceuticals Ltd ADR Daily Average True Range (ATR) ChartAslan Pharmaceuticals Ltd ADR Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aslan Pharmaceuticals Ltd ADR. The current obv is -316,695.

Aslan Pharmaceuticals Ltd ADR Daily On-Balance Volume (OBV) ChartAslan Pharmaceuticals Ltd ADR Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aslan Pharmaceuticals Ltd ADR. The current mfi is 4.60400401.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Aslan Pharmaceuticals Ltd ADR Daily Money Flow Index (MFI) ChartAslan Pharmaceuticals Ltd ADR Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aslan Pharmaceuticals Ltd ADR.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Aslan Pharmaceuticals Ltd ADR Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aslan Pharmaceuticals Ltd ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.027
Ma 20Greater thanMa 500.522
Ma 50Greater thanMa 1000.602
Ma 100Greater thanMa 2000.579
OpenGreater thanClose0.489
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Aslan Pharmaceuticals Ltd ADR with someone you think should read this too:
  • Are you bullish or bearish on Aslan Pharmaceuticals Ltd ADR? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aslan Pharmaceuticals Ltd ADR? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aslan Pharmaceuticals Ltd ADR

I send you an email if I find something interesting about Aslan Pharmaceuticals Ltd ADR.


Comments

How you think about this?

Leave a comment

Stay informed about Aslan Pharmaceuticals Ltd ADR.

Receive notifications about Aslan Pharmaceuticals Ltd ADR in your mailbox!